Glenmark partners Pfizer to launch Abrocitinib in India
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
Gabapentin is indicated for the management of Postherpetic Neuraligia
The registered capital of the newly founded company is € 50 million
Subscribe To Our Newsletter & Stay Updated